BioMarin agreed to acquire Alesta Therapeutics in a deal that totals $275 million upfront and up to $490 million including milestones for Alesta’s lead oral small-molecule candidate ALE-1. ALE-1 is in Phase I/IIa development for hypophosphatasia, a rare genetic bone disorder. The transaction signals BioMarin’s continued focus on mineralization biology and the inorganic pyrophosphate (PPi) pathway, an area where the company has previously invested. Analysts referenced BioMarin’s earlier decision to discontinue BMN-401, which also targeted the PPi axis. For BioMarin, integrating ALE-1 could broaden its skeletal disease franchise and potentially target a larger addressable market segment tied to hypophosphatasia. The company characterized the program as fitting within its skeletal disease portfolio and described the asset as having upside based on patient population reach. Deal terms and development plans will be key to watch, particularly if BioMarin seeks to differentiate ALE-1 on efficacy, tolerability, and commercial positioning versus existing or emerging mineralization therapies.